TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16731214
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (nortriptyline or fluoxetine)
Study: 9525302
Drug: smoking intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: smoking intervention plus bronchodilator
Study: 3611686
Drug: Milk tolerance
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk tolerance test (500 ml milk)
Study: 29150845
Drug: Sorbitol 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol 3.2 g
Study: 29150845
Drug: Sorbitol 10.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol 10.2 g
Study: 29150845
Drug: Sorbitol 13.4
Normalized name: docusate sodium 10 MG / sorbitol 13.4 GM Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol 13.4 g
Study: 29150845
Drug: Lamivudine 300
Normalized name: lamivudine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 300 mg alone
Study: 22112014
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream (subgroup analysis)
Study: 22112014
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (subgroup analysis)
Study: 20403940
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (LGG) at a dose of 10^9 colony-forming units in 100 mL of a fermented milk product (LGG group, n = 376)
Study: 17555526
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of antiepileptic drugs (CBZ)
Study: 14624771
Drug: r‐hGH 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐hGH 0.05 mg/kg/day (high dose)
Study: 14624771
Drug: r‐hGH 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐hGH 0.025 mg/kg/day (low dose)
Study: 7719072
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with prednisolone 1% eyedrops
Study: 7719072
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with indomethacin 1% eyedrops
Study: 7719072
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with prednisolone 1% + indomethacin 1% eyedrops
Study: 2043017
Drug: Pilocarpine hydrochloride
Normalized name: Pilocarpine Hydrochloride
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine hydrochloride (5-mg capsules, three times daily for 5 months)
Study: 6167116
Drug: 5% benzoyl
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% benzoyl peroxide preparation
Study: 30861337
Drug: GSK3389404 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3389404 (10 mg, 30 mg, 60 mg, 120 mg single doses)
Study: 30861337
Drug: GSK3389404 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3389404 (30 mg, 60 mg, 120 mg multiple doses, once weekly for 4 weeks)
Study: 19395585
Drug: Dasatinib 50
Normalized name: dasatinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 50 mg alone
Study: 19395585
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg given 10 hours before dasatinib
Study: 19395585
Drug: Antacid (Maalox)
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid (Maalox) 2 hours before dasatinib
Study: 19395585
Drug: Antacid (Maalox)
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid (Maalox) coadministered with dasatinib
Study: 17224718
Drug: Modafinil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (400 mg daily)
Study: 15131729
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application using a body wash containing 0.15% vitamin E and 0.10% vitamin E acetate
Study: 11669085
Drug: Mistletoe preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe preparation (Abnobaviscum Quercus) injected subcutaneously three times a week for 6 months
Study: 11669085
Drug: Pre-treatment observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment observation for 6 months
Study: 9536925
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide infusion (0.01 microgram min-1 kg-1)
Study: 795433
Drug: Diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucortolone valerate cream and ointment (0.1%)
Study: 795433
Drug: Diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucortolone valerate fatty ointment (0.1%)
Study: 25975558
Drug: Inosine tablets
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inosine tablets and vitamin C (Control)
Study: 23815742
Drug: Benidipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine (2 mg daily, increased to 8 mg daily)
Study: 23815742
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 mg daily, increased to 10 mg daily)
Study: 21528596
Drug: Calcichew D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcichew D3 tablets and acupoint catgut embedding
Study: 21528596
Drug: Calcichew D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcichew D3 tablets (oral administration)
Study: 21528596
Drug: Calcichew D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcichew D3 tablets and Xianling Gubao capsule (oral administration)
Study: 16845799
Drug: Continuously slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuously slow intravenous arsenic trioxide (As2O3) infusion regimen for 24 hours at an infusion rate of 8 drips per minute, total infusion duration of about 18-21 hours daily, daily dosage of 0.16 mg/kg
Study: 16845799
Drug: Routine regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine regimen with arsenic trioxide (As2O3) infusion at an infusion rate of 45-55 drips per minute, total infusion duration of about 2-3 hours daily, daily dosage of 0.16 mg/kg
Study: 16845799
Drug: Continuously slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuously slow intravenous arsenic trioxide (As2O3) infusion regimen
Study: 16845799
Drug: Routine regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine regimen with arsenic trioxide (As2O3) infusion
Study: 14665897
Drug: Concomitant use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant use of sildenafil (100 mg) and a vacuum entrapment device (VED)
Study: 9053968
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg intravenously)
Study: 2083851
Drug: Terconazole, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terconazole, 240 mg, one dose per day
Study: 2083851
Drug: Terconazole, 80
Normalized name: Terconazole, 80 mg vaginal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terconazole, 80 mg, daily dose for three days
Study: 2083851
Drug: Chlotrimazole, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlotrimazole, 200 mg, daily dose for three days
Study: 6161897
Drug: Macrodex 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrodex 6% (500 ml Dextran 60 infusion)
Study: 6161897
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl (500 ml)
Study: 26011677
Drug: ZS-9 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZS-9 5 g
Study: 26011677
Drug: ZS-9 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZS-9 15 g
Study: 17353471
Drug: IV immunoglobulin
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV immunoglobulin (IVIG) 2 g/kg
Study: 11152366
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg methionine
Study: 11152366
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg methionine plus 2 g of vitamin C
Study: 1634718
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of bupivacaine and fentanyl
Study: 1634718
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of fentanyl
Study: 30629280
Drug: Intranasal REMOXY
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal REMOXY ER (manipulated or intact)
Study: 30629280
Drug: Ground oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground oxycodone IR
Study: 24211813
Drug: Levofloxacin (LVFX)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin (LVFX) 500 mg administered orally
Study: 17237007
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen with 5-fluorouracil and folinic acid (FUFOL)
Study: 15978775
Drug: Onlay augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onlay augmentation
Study: 11886484
Drug: E2 +
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 + T (trimegestone 0.5 mg)
Study: 11886484
Drug: E2 (oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (oestradiol 2 mg)
Study: 11886484
Drug: E2 +
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 + D (dydrogesterone 10 mg)
Study: 10460069
Drug: Clomipramine 25
Normalized name: clomiPRAMINE 25 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 25 mg/day
Study: 10460069
Drug: Clomipramine 50
Normalized name: clomiPRAMINE 50 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 50 mg/day
Study: 10460069
Drug: Clomipramine 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 125 mg/day
Study: 10460069
Drug: Clomipramine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 200 mg/day
Study: 10460069
Drug: Clomipramine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (all doses)
Study: 7798508
Drug: Bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10 mg daily)
Study: 7798508
Drug: Nifedipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (2 x 20 mg)
Study: 7798508
Drug: Bisoprolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (20 mg daily)
Study: 2074163
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium 550 mg bid
Study: 2074163
Drug: pizotyline 0.5
Normalized name: pizotyline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pizotyline 0.5 mg tid
Study: 30696533
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray containing silver vitellinate, hyaluronic acid and sodium benzoate
Study: 30696533
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (sodium chloride 0.9%)
Study: 28058800
Drug: Negligible carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negligible carbohydrate snacks (up to 5.1 g carbohydrate and 276.3 kJ per portion)
Study: 25664905
Drug: i.v. ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ascorbate infusion
Study: 25664905
Drug: Ascorbate infusion
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbate infusion plus oral H1/H2 histamine receptor blockade
Study: 25664905
Drug: i.v. N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. N-acetylcysteine infusion
Study: 25091379
Drug: EPA+DHA supplementation
Normalized name: eicosapentaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA supplementation (0, 300, 600, 900, or 1,800 mg/d)
Study: 18922525
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (0.1 mg bolus with further boluses every 5 minutes as required)
Study: 11487483
Drug: Standard-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intravenous immunoglobulin (adults: 300 mg/kg every 4 weeks; children: 400 mg/kg every 4 weeks)
Study: 11487483
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (adults: 600 mg/kg every 4 weeks; children: 800 mg/kg every 4 weeks)
Study: 11487483
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin
Study: 11487483
Drug: Standard-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intravenous immunoglobulin
Study: 8110553
Drug: Diamorphine-bupivacaine mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine-bupivacaine mixture (0.0625% plain bupivacaine 6.25 mg h‐1 mixed with 0.005% diamorphine 0.5 mg h‐1)
Study: 8110553
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.125% plain bupivacaine 12.5 mg h‐1)
Study: 3074294
Drug: Insulin Protaphane
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Protaphane HM in Penfill
Study: 23212859
Drug: Early start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early start dialysis (eGFR 10 ‐ 14 mL/min/1.73 m²)
Study: 23212859
Drug: Late start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late start dialysis (eGFR 5 ‐ 7 mL/min/1.73 m²)
Study: 12176787
Drug: 3-week schedule
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week schedule of gemcitabine (1000 mg/m2 on days 1 and 8 of a 21-day cycle)
Study: 12176787
Drug: 4-week schedule
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week schedule of gemcitabine (1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle)
Study: 10210549
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with paclitaxel plus carboplatin
Study: 2203255
Drug: 90 mL
Normalized name: 190 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mL tap water ingested over 10 min
Study: 2203255
Drug: 90 mL
Normalized name: 190 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mL tap water ingested over 30 min
Study: 2203255
Drug: 600 mL
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mL tap water ingested over 10 min
Study: 2203255
Drug: 600 mL
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mL tap water ingested over 30 min
Study: 30096704
Drug: pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 10 mg/kg every 2 or 3 weeks for 24 months
Study: 30096704
Drug: ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 3 mg/kg every 3 weeks for four doses
Study: 26823338
Drug: Measles-Rubella Vaccine
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles-Rubella Vaccine + Human Rotavirus Vaccine (MR + HRV)
Study: 26823338
Drug: Measles-Rubella Vaccine
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles-Rubella Vaccine (MR)
Study: 22770867
Drug: Nasal gel
Normalized name: Nasal Gel
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal gel administered using a radial-hole inhaler
Study: 22770867
Drug: Different administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different administration methods
Study: 19913325
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with carboplatin (AUC=5) and docetaxel (75mg/m2) every 3 weeks for four cycles, initiated 1-4 weeks post-surgery, with prophylactic G-CSF supportive therapy.
Study: 11978748
Drug: Oligosaccharide supplemented
Normalized name: chitosan oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligosaccharide supplemented formula (10 g/l)
Study: 9988877
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of vitamin A (50,000 IU per day, median; range 10,000-300,000 IU per day)
Study: 9988877
Drug: Nonteratogenic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonteratogenic agent exposures (control group 2)
Study: 7787131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of 14C-FOX 988 (gelatin capsules) with a meal (50% fat by calories) immediately following dosing
Study: 7787131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of 14C-FOX 988 (gelatin capsules) with a meal (50% fat by calories) at 2 h post-dose
Study: 7787131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of 14C-FOX 988 (suspension, 0.5% CMC) with a meal (50% fat by calories) immediately following dosing
Study: 7787131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of 14C-FOX 988 (suspension, 0.5% CMC) with a meal (50% fat by calories) at 2 h post-dose
Study: 7787131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of 14C-FOX 988 (gelatin capsules)
Study: 7787131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of 14C-FOX 988 (suspension, 0.5% CMC)
Study: 25830381
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol 50/25 mcg
Study: 25830381
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol 100/25 mcg
Study: 25830381
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol 200/25 mcg
Study: 21378714
Drug: Cytoflavine preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavine preparation as energy-correction and antioxidant
Study: 21378714
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cytoflavine with calcium-D3
Study: 17594775
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/calcium-placebo
Study: 17594775
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/elemental calcium 1000 mg
Study: 17594775
Drug: Alendronate-containing treatments
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate-containing treatments
Study: 17594775
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg with calcium 1000 mg
Study: 12044254
Drug: Rapid‐acting anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid‐acting anesthetic agents (midazolam, propofol) for refractory status epilepticus
Study: 2667336
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg before meals
Study: 973984
Drug: Rifampicin and
Normalized name: rifampicin and isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin and Isoniazid in combination
Study: 22105039
Drug: Lady 4
Normalized name: Lady's Thistle Seed
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lady 4 (2 capsules daily)
Study: 19568738
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (n = 17)
Study: 19568738
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (n = 15)
Study: 14744726
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122)
Study: 14744726
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori treatment (omeprazole, amoxicillin, clarythromycin)
Study: 11698315
Drug: i.v. dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. dexamethasone 5 mg
Study: 3591496
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (career development training sessions)
Study: 30153988
Drug: Post-procedure bivalirudin
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-procedure bivalirudin infusion
Study: 28358599
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg up to 500 mg per day for 4 weeks)
Study: 26237812
Drug: Omnic (tamsulosin)
Normalized name: Omni Gel
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omnic (tamsulosin) 0.4 mg once daily for 8 years
Study: 26237812
Drug: Herbal preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal preparations (Gentos, Tadenan, or Speman)
Study: 21418799
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/benazepril 10 mg once-daily (combination therapy)
Study: 21418799
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg monotherapy
Study: 14756429
Drug: Neo-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant chemotherapy (3 cycles of CEF before and 3 cycles after surgery)